LUNG CANCER

January 18th 2025

In separate, live virtual events, Vincent K. Lam, MD, and Chul Kim, MD, MPH, discuss molecular assays and treatment options for a patient with metastatic non–small cell lung cancer (NSCLC), with participants.

January 15th 2025

During a Case-Based Roundtable® event, Joshua K. Sabari, MD, continued discussion of key outcomes from the MARIPOSA trial and toxicity management in patients with EGFR-mutated non–small cell lung cancer in the second article of a 2-part series.

January 8th 2025

Abenacianine, a tumor-targeted fluorescent imaging agent, received fast track designation from the FDA after demonstrating its safety and efficacy in visualizing lung tumors in a phase 2 study.

January 6th 2025

The phase 1 INSIGHT-003 trial of efti, pembrolizumab, and chemotherapy for first-line advanced nonsquamous NSCLC has completed enrollment.